0KCC Stock Chart & Stats
$4.81
-$0.07(-1.46%)
At close: 4:00 PM EDT
$4.81
-$0.07(-1.46%)
Day’s Range― - ―
52-Week Range$2.43 - $7.77
Previous CloseN/A
Volume350.00
Average Volume (3M)240.00
Market Cap
$150.15M
Enterprise Value$87.36
Total Cash (Recent Filing)$28.20M
Total Debt (Recent Filing)$3.07M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Aug 06, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding32,290,170
10 Day Avg. Volume693
30 Day Avg. Volume240
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.50Price Target Upside118.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.84
Revenue Forecast (FY)$2.15M
Bulls Say, Bears Say
Bulls Say
FDA Submission & Regulatory EngagementA submitted FDA application with productive engagement materially de-risks U.S. commercialization timing and creates a clear pathway to first orders and recurring test revenue. Durable regulatory progress supports long-term market access and payer conversations, improving the odds of sustainable commercial scale.
Quality Certification (ISO 13485)ISO 13485 certification establishes a regulated-quality manufacturing and quality management foundation required for lab kit commercialization and partner confidence. This durable compliance reduces operational friction in launches, supports international regulatory filings, and enables scalable production for long-term revenue growth.
Established Reimbursement BenchmarkA Medicare reimbursement rate above $2,700 creates a structural pricing and revenue foundation for test adoption and hospital economics. Durable payer coverage reduces commercialization uncertainty, supports ASP assumptions and unit economics, and enhances the potential for profitable margins once volumes scale.
Bears Say
Sharp Revenue DeclineA greater-than-50% TTM revenue decline signals weak demand traction and raises structural doubts about market adoption pace. Persistent low top-line undermines scalability, increases per-unit fixed cost burden, and lengthens the time required to achieve the high-margin profile management targets.
Sustained Cash Burn And Negative Cash FlowVery large negative operating and free cash flow indicate the business is not self-funding and requires ongoing external capital. Persistent high burn constrains runway, forces management to prioritize financing over scaling, and elevates execution risk around regulatory/commercial milestones.
Negative Shareholders' Equity / Balance-sheet StressNegative equity reflects cumulative losses that reduce financial flexibility and increase dilution/refinancing sensitivity. This structural weakness can limit borrowing options, raise funding costs, and make successful long-term commercialization contingent on timely capital raises or rapid conversion to positive free cash flow.
Insight Molecular Diagnostics News
0KCC FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest share price was $2.42 and its highest was $7.77 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $150.15M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on May 13, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.262 by $0.142.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Insight Molecular Diagnostics dividends here
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.24.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,290,170 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.262. Following the earnings report the stock price went up 21.033%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in GB:0KCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (118.30% Upside)
$10.50 (118.30% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
112.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.02%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
0KCC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents clear operational and regulatory progress (FDA submission engagement, ISO certification, registry momentum, pricing validation, TAM affirmation, emerging head-to-head data and organ expansion), balanced against near-term financial pressures (Q2 cash burn >$9M, very low near-term revenue ~$0.25M), commercialization constraints (instrument placement), and timing uncertainty in Europe and FDA review details. Management provided concrete targets for margins, cost structure, and runway management and expects cash burn to decline in the back half of the year. Overall, the call signals meaningful de-risking and commercialization preparation while acknowledging near-term financial drag.View all GB:0KCC earnings summaries0KCC Stock 12 Month Forecast
Average Price Target
$10.50
▲(118.30% Upside)
Technical Analysis
Atossa Therapeutics
―
MacroGenics
―
Elutia
―
Surrozen
―
Telomir Pharmaceuticals, Inc.
―